To study complex biological processes holistically, it is imperative to take an integrative
approach that combines multi-omics data to highlight the interrelationships of the involved …

Immune checkpoint inhibitors (ICIs) have substantially improved the survival of cancer
patients over the past several years. However, only a minority of patients respond to ICI …

Checkpoint blockade therapies that reactivate tumour-associated T cells can induce durable
tumour control and result in the long-term survival of patients with advanced cancers …

Single-cell RNA-sequencing has emerged as a powerful technique for characterizing
cellular heterogeneity, but it is currently impractical on large sample cohorts and cannot be …

Over the past decade, melanoma has led the field in new cancer treatments, with impressive
gains in on-treatment survival but more modest improvements in overall survival. Melanoma …

Checkpoint inhibitor-based immunotherapies that target cytotoxic T lymphocyte antigen 4
(CTLA4) or the programmed cell death 1 (PD1) pathway have achieved impressive success …

Oncogenic activation of the phosphatidylinositol-3-kinase (PI3K), protein kinase B
(PKB/AKT), and mammalian target of rapamycin (mTOR) pathway is a frequent event in …

Immune checkpoint blockade therapy has demonstrated promising clinical outcomes for
multiple cancer types. However, the emergence of resistance as well as inadequate …

Neoantigens play a key role in the recognition of tumour cells by T cells; however, only a
small proportion of neoantigens truly elicit T-cell responses, and few clues exist as to which …

Tumor microenvironment (TME) cells constitute a vital element of tumor tissue. Increasing
evidence has elucidated their clinicopathologic significance in predicting outcomes and …